Press releases
Press releases dating back to 2018 are available below. Search them by keyword or browse by year/business category.
Press releases for other local operating companies can be viewed on the local websites.
-
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review
Read more -
GSK welcomes agreement with the Government of Canada for the provision of pandemic and seasonal influenza vaccines
GSK welcomes agreement with the Government of Canada for the provision of pandemic and seasonal influenza vaccines
Read more -
Regulatory submission for GSK’s daprodustat accepted into Health Canada review
GSK announces that Health Canada has accepted into review the New Drug Submission (NDS) for daprodustat
Read more -
GSK Canada unveils new head office, embracing a hybrid working model centred around individual and collective performance and personal well-being
GSK Canada unveils new head office, embracing a hybrid working model
Read more -
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
Read more -
GSK announces independent Consumer Healthcare company is to be called Haleon
GSK announces independent Consumer Healthcare company is to be called Haleon
Read more -
GSK announces additional purchase agreements with the Government of Canada for COVID-19 monoclonal antibody therapy, Sotrovimab
GSK announces additional purchase agreements with the Government of Canada for COVID-19 monoclonal antibody therapy, Sotrovimab
Read more -
GSK’s JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer
GSK’s JEMPERLI (dostarlimab for injection) approved in Canada
Read more -
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Read more -
SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
Read more -
For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
Read more -
NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults
Read more -
VOLUNTARILY RECALL OF TUMS EXTRA STRENGTH (750MG) ASSORTED BERRY 100CT AND ROLL 3X8CT
VOLUNTARILY RECALL OF TUMS EXTRA STRENGTH (750MG) ASSORTED BERRY 100CT AND ROLL 3X8CT
Read more -
GSK announces purchase agreement with the Government of Canada for COVID-19 monoclonal antibody therapy, sotrovimab
GSK announces purchase agreement with the Government of Canada for COVID-19 monoclonal antibody therapy, sotrovimab
Read more -
Important information on Advil Cold & Sinus Daytime / Nighttime Convenience Pack
Important information on Advil Cold & Sinus Daytime / Nighttime Convenience Pack
Read more -
Changing attitudes to vaccination post-COVID suggest investing in our own health is a key priority for many Canadians
Changing attitudes to vaccination post-COVID suggest investing in our own health is a key priority for many Canadians
Read more -
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
Read more -
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and
Read more -
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
Read more -
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines and prescribed vaccines
-
Research & development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products.
-
Careers
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
